PIN41 Cost-Effectiveness of Pertussis Adolescent Booster in England and Wales: A Dynamic Model Based Analysis  by Terlinden, A. et al.
Anargyroi Hospital, Athens, Greece, 9Intensive Care Unit, University Hospital of Ioannina,
Ioannina, Greece, 10Intensive Care Unit, Ag. Olga General Hospital, Athens, Greece, 11Intensive
Care Unit, Piraeus General Hospital, Piraeus, Greece, 12General Intensive Care Unit, Tzaneio
General Hospital, Piraeus, Greece, 13Intensive Care Unit, General Hospital of Eleusis “Thriassion”,
Athens, Greece, 14Intensive Care Unit, University Hospital of Heraklion, Crete, Greece,
15Department of Intensive Care Medicine, University Hospital of Alexandroupolis,
Alexandroupolis, Greece, 16Department of Critical Care, University Hospital of Larissa, Larissa,
Greece
OBJECTIVES: The ESTIMATOR study aims to provide information on clinical and
economic outcomes associated with the management of fungal infections across
intensive care units (ICUs) in Greece. METHODS: ESTIMATOR was a non-interven-
tional prospective cohort study conducted in 14 ICUs in Greece. Adult patients
initiating therapy with a systemic antifungal agent between July 2011 and February
2012 were included. Information on predisposing factors, management and thera-
peutic strategies, clinical outcomes and length of ICU stay (LOICUS) were recorded
until end of therapy or death. RESULTS: A total of 155 eligible patients were re-
cruited. 68% of patients presented at least 5 predisposing factors for fungal infec-
tion at antifungal treatment (AT) onset, while the mean APACHE score was 22.4
(s.d. 5.9). Median time until AT initiation was 6 days after ICU admission, while the
median LOICUS was 31 days. 49.7% of patients received treatment with an empiric
strategy while prophylaxis, pre-emptive and definitive strategies where used at
6.4%, 20.0% and 23.9% of the study population respectively. Echinocandins (57.3%),
Fluconazole (20.0%) and Itraconazole (12.9%) were the most utilized therapies in
the study. The overall treatment success and mortality rates were 43.9% and 49.7%
respectively. Variations in death and response rates were observed when adjusted
to the treatment strategy and the class of drug used. The mean total cost per
patient treated was estimated at 22,012 Euros. Average LOICUS accounts for the
80.8% of total direct costs, while antifungal treatment, tests and investigations
account for the remaining 19.2%. Limited efficacy of first line antifungal agent is
associated with an increase in economic costs of 74%. CONCLUSIONS: Treating
patients for fungal infections imposes a high economic burden to hospitals. Signif-
icant cost drivers are prolonged LOICUS and treatment failure. Treatment options
that result in LOICUS reduction and increased first line efficacy have the potential
to reduce hospital cost.
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OBJECTIVES: Neisseria meningitidis is a leading cause of life-threatening invasive
meningococcal diseases (IMD). In most populated Canadian provinces, vaccination
with the monovalent vaccine (MenC; against serogroup C) is recommended at one
year of age. This study aimed to assess various quadrivalent vaccination strategies
(MenACWY-TT covering serogroups A, C, W135 and Y) schedule (12 months with
and without booster at 12 or 15 years) in Canada compared to the current strategy.
METHODS: IMD incidence under the different scenarios was estimated using a
dynamic model. The cost associated with IMD treatment, IMD sequelae and IMD
mortality were estimated. Input data (mortality, rates of sequelae and costs) were
retrieved from Canadian statistics and published studies. The time horizon was 50
years. A discount rate of 5% was applied on costs. Costs were estimated from the
third-party payer (TPP) and the societal perspective (accounting for the productivity lost
from IMD and its sequelae). Deterministic and probabilistic sensitivity analyses were
conducted. RESULTS: Compared with MenC at 12 months, MenACWY-TT at 12
months was estimated to prevent an additional 862 IMD cases and 76 deaths, 3,362
IMD cases and 296 deaths with a booster at 12 years and 4,007 IMD cases and 353
deaths with a booster at 15 years. The treatment costs averted while switching to
the MenACWY-TT vaccine were estimated at C$8.4 (no booster), C$31.9 ( booster
at 12 years) and C$39.6 millions ( booster at 15 years) from the TPP perspective and
respectively C$24.0, C$89.8 and C$112.2 millions from the societal perspective.
Results were most sensitive to the incidence of IMD and serogroup-specific inci-
dence of post-IMD sequelae. CONCLUSIONS: The model predicted that vaccinating
with MenACWY-TT at 12 months with an adolescent booster would result in addi-
tional IMD and cost reduction compared to the current MenC at 12 months.
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OBJECTIVES: SPRINT-2 and RESPOND-2 randomized clinical trials have demon-
strated substantially higher sustained virologic response rates (SVR) for bocepre-
vir-based treatment compared to peginterferon and ribavirin (PR) alone in patients
with chronic genotype 1 HCV infection. Our objective was to evaluate the cost-
effectiveness of using boceprevir in Germany from the perspective of German Stat-
utory Health Insurance (SHI). METHODS: A Markov model was created to project
the effect of antiviral therapy options on Hepatitis C disease progression using
German life tables and baseline patient demographics from the trials - mean age,
gender, and fibrosis stage distribution. The first part of the model simulated two
strategies - treatment with boceprevir/peginterferon/ribavirin (as defined by the
European Medicines Agency) and treatment with peginterferon/ribavirin. The sec-
ond part of the model projected lifetime incidences of decompensated cirrhosis,
hepatocellular carcinoma, liver-transplant, and liver-related death. All hepatitis
C-related state transition probabilities were obtained from previously published
studies. Pharmacy retail prices minus rebates (Social code book V, § 130 (1) and §
130a (1a)) were used. The model was validated with previously published studies
and probabilistic sensitivity analysis was performed. RESULTS: Liver-related mor-
bidity and mortality were projected to be reduced by 43% to 53%. for a quality
adjusted life year (QALY) gain of 0.8 in treatment naïve patients, and 1.4 in treat-
ment experienced patients in comparison with SOC. The cost per QALY gained on
boceprevir-based regimes compared to PR alone was 17,511€ for treatment naïve
patients and 16,645€ for treatment experienced patients in comparison with SOC.
CONCLUSIONS: In German SHI, the addition of boceprevir to PR in patients with
chronic genotype 1 HCV infection reduces liver-related morbidity and mortality in
a quantifiable and cost-effective fashion, irrespective of whether patients have
been previously treated.
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OBJECTIVES: Epidemiology of pertussis shows that despite effective vaccination in
childhood, naturally acquired and vaccine induced immunity is waning over time
leading to higher incidence in adolescents and adults. Literature estimates the
annual incidence of pertussis in the UK reaches 330/100,000 compared with an
incidence of 4/100,000 based on statutory notifications, highlighting the degree of
under-reporting. This analysis examines the cost-effectiveness of the addition of
an adolescent routine booster vaccination against pertussis to the schedule in
England and Wales from a payer perspective. METHODS: An age stratified, com-
partmental dynamic model was developed and calibrated on HPA data corrected
for symptomatic and asymptomatic cases and empirical contact rates. Two sce-
narios were compared: current pertussis vaccination schedule (2, 3, and 4 months
of age) and a similar schedule with additional booster vaccination at 15 years with
coverage of 59%. Total costs and quality adjusted life years (QALYs) were
estimated. RESULTS: At equilibrium pertussis booster vaccination at 15 years is
projected to reduce the combined reported and unreported incidence of pertussis
in the following age categories: 10-19 years (55.0%), 20-59 years (31.3%) and 60-75
years (27.9%). There are 7155 QALYs gained annually in the UK population. Unre-
ported symptomatic cases were assumed to incur no cost and 50% of the QALY
benefit of reported cases but provided 98% of the total quality of life gained through
total symptomatic cases. Annual implementation costs (£9.4M) would be partially
offset by savings associated with reported cases (£1.5M). The incremental cost per
QALY would be £1,103 from a payer perspective. CONCLUSIONS: Model projection
indicates that adolescent routine booster vaccination against pertussis would re-
duce pertussis burden, and is likely to be cost-effective from a payer perspective.
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OBJECTIVES: Due to the fact that an infection with the Hepatitis-C-Virus usually
runs chronic, this disease represents a major public-health challenge. Hence, the
aim of this study is to evaluate the treatment of the Hepatitis-C-Infection with the
standard-therapy Peg-IFN2a in combination with Ribavirin vs. the combination-
therapy Peg-IFN2a, Ribavirin and Telaprevir. METHODS: For the decision tree
analysis model, an extended cost-per-cure-analysis was performed. The used data
derived from two large-scale double-blind, randomized, placebo-controlled Phase-
III-Studies by Jacobson et al. (2011) and Zeuzem et al. (2011). The modeling was
performed for the time horizons of 24 weeks, 48 weeks, respectively, which corre-
spond to the duration of therapy. Examined patients were adults who were either
treatment-experienced or treatment-naïve patients. RESULTS: The costs per re-
sponder in the group of previous relapser with the Telaprevir-combination-ther-
apy amount to €47,097.89. In the control-group, the standard-care of treatment
caused costs per responder of €80,563.05. For the combination-therapy with Tel-
aprevir this results in a cost-advantage of €33,465.16 (42%) per responder. Costs per
responder in the previous partial responders amount to €78,541.24 for the Telapre-
vir-containing regimen. In the control-group, the standard-therapy caused
€128,900.89 (cost advantage of €50,359.65 (39%) for the combination-therapy). The
costs-per-responder in the group of previous non-responders amount to
€159,790.80 for the triple-therapy, compared to the standard-therapy with
€386,702.66, resulting in a cost-advantage per responder of €226,911.86 (59%) for the
combination-therapy. Total costs of the Telaprevir-containing therapy with naïve-
patients amount to €54,410.53 per responder, compared to the control-group with
€43,943.48, causing a cost disadvantage of €10,467.05 per responders (24%) for the
combination-therapy with Telaprevir. Across all patient groups, a cost advantage
per responder of €50,298.68 (42%) incurred (standard therapy Peg-IFN2a and Riba-
virin: €118,559.52, combination-therapy with Telaprevir: €68,260.84).
CONCLUSIONS: The results of the analysis show that the combination-therapy
with Telaprevir is the dominant strategy in the treatment of chronic Hepatitis-C
Genotype-1 in Austria.
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